TSHA Stock Price, Taysha Gene Therapies Quote, Chart

Market Summary

USD3.10-0.04

Market Closed

-1.27%

TSHA Stock Price

View Fullscreen

TSHA RSI Chart

TSHA Valuation

Market Cap

579.8M

Price/Earnings (Trailing)

-4.91

Price/Sales (Trailing)

40.95

Price/Free Cashflow

-7.97

TSHA Price/Sales (Trailing)

TSHA Profitability

Return on Equity

-219.14%

Return on Assets

-77.13%

Free Cashflow Yield

-12.55%

TSHA Fundamentals

TSHA Revenue

Revenue (TTM)

14.2M

Rev. Growth (Yr)

-27.43%

Rev. Growth (Qtr)

-5.43%

TSHA Earnings

Earnings (TTM)

-118.0M

Earnings Growth (Yr)

-36.54%

Earnings Growth (Qtr)

-150.4%

Breaking Down TSHA Revenue

Last 7 days

32.5%

Last 30 days

26.5%

Last 90 days

62.3%

Trailing 12 Months

342.9%

How does TSHA drawdown profile look like?

TSHA Financial Health

Current Ratio

3.38

Debt/Equity

0.75

Debt/Cashflow

-1.79

TSHA Investor Care

Shares Dilution (1Y)

191.40%

Diluted EPS (TTM)

-0.64

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	14.2M	0	0	0
2023	5.7M	9.0M	12.2M	15.4M
2022	0	0	0	2.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Taysha Gene Therapies Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 02, 2024	alam kamran	sold (taxes)	-1,944	1.51	-1,288	chief financial officer
Jan 02, 2024	alam kamran	acquired	-	-	590,413	chief financial officer
Jan 02, 2024	nagendran sukumar	acquired	-	-	863,617	president and head of r&d
Jan 02, 2024	nolan sean p.	acquired	-	-	1,184,690	chief executive officer
Nov 17, 2023	manning paul b	bought	163,000	1.63	100,000	-
Aug 24, 2023	alam kamran	sold	-76,890	2.33	-33,000	chief financial officer
Aug 16, 2023	manning paul b	bought	14,820,000	0.9	16,466,700	-
Aug 16, 2023	donenberg phillip b.	bought	99,999	0.9	111,111	-
Aug 16, 2023	nolan sean p.	bought	400,000	0.9	444,444	chief executive officer
Aug 16, 2023	stalfort john a iii	bought	350,000	0.9	388,889	-

Which funds bought or sold TSHA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Artal Group S.A.	added	0.67	4,099,260	10,583,300	0.27%
May 16, 2024	JANE STREET GROUP, LLC	added	39.28	94,171	169,003	-%
May 15, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	reduced	-70.56	-175,668	160,413	0.01%
May 15, 2024	MORGAN STANLEY	added	2,287	14,451,400	14,834,700	-%
May 15, 2024	ADAR1 Capital Management, LLC	reduced	-79.19	-245,085	124,845	0.03%
May 15, 2024	Point72 Asset Management, L.P.	reduced	-58.59	-1,562,780	3,194,980	0.01%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-99.99	-4,066,110	566	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	1,168	2,891,470	3,039,220	-%
May 15, 2024	Graham Capital Management, L.P.	sold off	-100	-50,404	-	-%
May 15, 2024	MARSHALL WACE, LLP	new	-	2,957,990	2,957,990	-%

Are Funds Buying or Selling TSHA?

Are funds buying TSHA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TSHA

No. of Funds

Unveiling Taysha Gene Therapies Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	venrock healthcare capital partners iii, l.p.	5.6%	10,412,872	SC 13G/A
Feb 14, 2024	rtw investments, lp	9.8%	18,505,556	SC 13G
Feb 14, 2024	ra capital management, l.p.	9.99%	18,670,089	SC 13G/A
Feb 09, 2024	tcg crossover gp i, llc	1.6%	2,912,861	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Sep 11, 2023	fmr llc	-	0	SC 13G/A
Aug 28, 2023	venrock healthcare capital partners iii, l.p.	7.7%	14,444,444	SC 13G
Aug 25, 2023	tcg crossover gp i, llc	5.9%	11,111,111	SC 13G
Aug 25, 2023	ra capital management, l.p.	9.99%	18,690,868	SC 13G
Aug 21, 2023	manning paul b	12.6%	23,476,333	SC 13D/A

Recent SEC filings of Taysha Gene Therapies Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
Apr 18, 2024	DEFA14A	DEFA14A
Apr 18, 2024	DEF 14A	DEF 14A
Apr 18, 2024	ARS	ARS
Mar 19, 2024	S-8	Employee Benefits Plan
Mar 19, 2024	8-K	Current Report
Mar 19, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Taysha Gene Therapies Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Taysha Gene Therapies Inc News

Latest updates

Taysha Gene Therapies Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)								(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2
Revenue	-5.4%	3,411	3,607	4,746	2,395	4,700	3,264	1,828	392
Operating Expenses	39.8%	27,741	19,850	20,996	25,779	21,265	56,468	25,457	33,373
S&GA Expenses	-100.0%	-	6,719	8,589	5,988	8,751	7,341	8,683	9,867
R&D Expenses	62.9%	20,657	12,682	11,791	19,791	12,514	12,707	16,774	23,506
Interest Expenses	86.4%	1,329	713	1,471	1,440	1,374	1,305	1,078	743
Net Income	-150.4%	-24,061	47,741	-117,087	-24,598	-17,622	-55,078	-26,527	-34,092
Net Income Margin	-15.4%	-8.33*	-7.22*	-17.56*	-13.80*	-23.23*	-66.35*	-	-
Free Cashflow	-23.6%	-19,938	-16,134	-17,949	-18,719	-24,085	12,403	-30,830	-41,216

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-11.4%	153	173	196	82.00	102	126	111	142	166	214	241	242	243	259	279	-
Current Assets	-12.9%	131	150	172	54.00	72.00	96.00	43.00	77.00	107	160	197	207	240	258	279	0.00
Cash Equivalents	-13.9%	124	144	164	45.00	63.00	88.00	34.00	66.00	97.00	149	189	197	229	251	279	-
Net PPE	-1.3%	11.00	11.00	11.00	14.00	15.00	15.00	64.00	61.00	55.00	51.00	41.00	34.00	2.00	0.00	0.00	-
Liabilities	1.4%	99.00	98.00	245	119	117	125	100	110	115	119	101	55.00	20.00	8.00	12.00	-
Current Liabilities	5.1%	39.00	37.00	180	51.00	54.00	63.00	33.00	43.00	49.00	52.00	43.00	28.00	19.00	7.00	12.00	0.00
Long Term Debt	0.0%	41.00	41.00	39.00	38.00	38.00	38.00	38.00	38.00	37.00	37.00	28.00	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	41.00	39.00	38.00	38.00	38.00	38.00	38.00	37.00	37.00	28.00	-	-	-	-	-
Shareholder's Equity	-28.1%	54.00	75.00	-	-	-14.95	1.00	11.00	33.00	51.00	95.00	140	186	223	251	268	-
Retained Earnings	-4.7%	-537	-513	-560	-443	-419	-401	-345	-319	-285	-235	-185	-134	-93.15	-61.13	-42.81	-1.11
Additional Paid-In Capital	0.5%	591	588	512	407	404	402	357	352	336	331	326	321	316	312	310	1.00
Shares Outstanding	0.0%	187	187	187	64.00	63.00	63.00	40.00	40.00	38.00	38.00	37.00	37.00	37.00	-	-	-
Float	-	-	-	-	30.00	-	-	-	92.00	-	-	-	479	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	-22.8%	-19,798	-16,117	-17,949	-18,767	-20,185	14,712	-28,810	-33,353	-40,939	-40,258	-31,933	-22,816	-22,035	-19,848	-6,716	-2,466	-1,699	-	-
Share Based Compensation	62.5%	3,198	1,968	2,040	2,222	1,675	4,103	4,470	4,141	5,329	4,955	5,086	4,549	3,594	2,013	1,341	-	-	-	-
Cashflow From Investing	-1300.0%	-140	-10.00	-3,490	48.00	-3,900	-2,370	-3,020	-8,113	-11,427	-8,520	-4,002	-8,498	-534	-6,051	-31.00	-3,000	-	-	-
Cashflow From Financing	99.5%	-22.00	-4,248	140,634	377	-370	41,232	-103	11,075	-107	9,105	-	-	-	-1,482	274,181	338	18,027	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TSHA Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 3,411	$ 4,706
Operating expenses:
Research and development	20,657	12,514
General and administrative	7,084	8,751
Total operating expenses	27,741	21,265
Loss from operations	(24,330)	(16,559)
Other income (expense):
Change in fair value of warrant liability	(337)
Change in fair value of term loan	(1,053)
Interest income	1,693	319
Interest expense	(29)	(1,374)
Other expense	(5)	(8)
Total other income (expense), net	269	(1,063)
Net loss	$ (24,061)	$ (17,622)
Net loss per common share, basic	$ (0.1)	$ (0.28)
Net loss per common share, diluted	$ (0.1)	$ (0.28)
Weighted average common shares outstanding, basic	231,249,344	63,260,905
Weighted average common shares outstanding, diluted	231,249,344	63,260,905

TSHA Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 123,980	$ 143,940
Restricted cash	449	449
Prepaid expenses and other current assets	4,168	3,479
Assets held for sale	2,000	2,000
Total current assets	130,597	149,868
Restricted cash	2,151	2,151
Property, plant and equipment, net	10,686	10,826
Operating lease right-of-use assets	9,261	9,582
Other non-current assets	304	304
Total assets	152,999	172,731
Current liabilities
Accounts payable	10,380	6,366
Accrued expenses and other current liabilities	13,562	12,284
Deferred revenue	14,695	18,106
Total current liabilities	38,637	36,756
Term loan, net	40,512	40,508
Operating lease liability, net of current portion	18,499	18,953
Other non-current liabilities	1,502	1,577
Total liabilities	99,150	97,794
Commitments and contingencies - Note 13
Stockholders' (deficit) equity
Preferred stock, $0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of March 31, 2024 and December 31, 2023
Common stock, $0.00001 par value per share; 400,000,000 shares authorized and 187,018,275 and 186,960,193 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	2	2
Additional paid-in capital	591,166	587,942
Accumulated other comprehensive loss	(251)
Accumulated deficit	(537,068)	(513,007)
Total stockholders' equity	53,849	74,937
Total liabilities and stockholders' equity	$ 152,999	$ 172,731

About Taysha Gene Therapies Inc

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

CEO	Mr. Sean P. Nolan
WEBSITE	tayshagtx.com
INDUSTRY	Biotechnology
EMPLOYEES	65

Taysha Gene Therapies Inc Frequently Asked Questions

What is the ticker symbol for Taysha Gene Therapies Inc? What does TSHA stand for in stocks?

TSHA is the stock ticker symbol of Taysha Gene Therapies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Taysha Gene Therapies Inc (TSHA)?

As of Fri May 17 2024, market cap of Taysha Gene Therapies Inc is 579.76 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TSHA stock?

You can check TSHA's fair value in chart for subscribers.

What is the fair value of TSHA stock?

You can check TSHA's fair value in chart for subscribers. The fair value of Taysha Gene Therapies Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Taysha Gene Therapies Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TSHA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Taysha Gene Therapies Inc a good stock to buy?

The fair value guage provides a quick view whether TSHA is over valued or under valued. Whether Taysha Gene Therapies Inc is cheap or expensive depends on the assumptions which impact Taysha Gene Therapies Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TSHA.

What is Taysha Gene Therapies Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, TSHA's PE ratio (Price to Earnings) is -4.91 and Price to Sales (PS) ratio is 40.95. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TSHA PE ratio will change depending on the future growth rate expectations of investors.